SANUWAVE Health Announces Successful Filing of Patent for Use of Shockwaves to Treat Respiratory Ailments, Including Viral Infections Such as COVID-19
Concept Submitted to National Science Foundation for Funding Grant
Suwanee, Ga - 
(NewMediaWire) - April 09, 2020 - SANUWAVE Health, Inc. (OTCQB: SNWV) announced
today the successful filing of a patent for use of shockwaves to treat
respiratory ailments including viral infections such as COVID-19, Chronic
Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Idiopathic Pulmonary
Fibrosis (IPF), Pneumonia and Bronchitis. SANUWAVE has also submitted a
grant proposal to the NSF (National Science Foundation) for Phase 1 funding to
explore clinical research in the area of respiratory ailments, specifically on
the treatment of COVID-19 and its debilitating health effects. The
research on this subject will be done in partnership with fellow researchers at
Montana State University’s Center for Biofilm Engineering.
Commenting
on the patent filings, Kevin A. Richardson II, Chairman of the Board and CEO of
SANUWAVE, said, "Every healthcare company in the US is working diligently
to help solve and treat the COVID-19 pandemic. SANUWAVE’s team consulted
with our clinical and science advisors and determined we could use our
energy-based proprietary technology to help clear the lungs of mucus and/or
change the viscosity of mucus, therefore, easing the constriction of the
respiratory system from the mucus build up due to COVID-19. The treatment
would be similar to percussion therapy currently being used but would use
shockwave as a mechanism of action, which can allow for more focus and power
when necessary. We had been exploring use of our technology to treat
other respiratory ailments for quite some time, but with this crisis in the
forefront, we are accelerating our research to help treat patients."
Iulian
Cioanta, Ph.D., Chief Science and Technology Officer of SANUWAVE Health, added,
“With over 82 patents and patents pending in our portfolio, SANUWAVE has one of
the most extensive IP-portfolios in the shockwave industry. Our team has
been exploring respiratory ailment treatment for quite some time. We know
from previously published clinical work that our technology produces a
modulation of inflammation, to reduce the detrimental immune system
overreaction, and at the same time increases vascularization. This should
aid in the healing, lessen the pain in the patients suffering from COVID-19,
and ultimately reduce scarring and sequalae to improve lung oxygenation.
We have a strong working relationship with Montana State University’s Center
for Biofilm Engineering on biofilms, they are very familiar with our
technology, and have the capabilities to explore respiratory indications.”
About
SANUWAVE Health, Inc.
SANUWAVE
Health, Inc. (OTCQB: SNWV) is a shockwave technology company initially focused
on the development and commercialization of patented noninvasive, biological
response activating devices for the repair and regeneration of skin,
musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of
regenerative medicine products and product candidates activate biologic
signaling and angiogenic responses, producing new vascularization and
microcirculatory improvement, which helps restore the body’s normal healing
processes and regeneration. SANUWAVE applies its patented PACE® technology in
wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its
lead product candidate for the global wound care market, dermaPACE®, is US FDA
cleared for the treatment of Diabetic Foot Ulcers. The device is also CE
Marked throughout Europe and has device license approval for the treatment of
the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New
Zealand. SANUWAVE researches, designs, manufactures, markets and services its
products worldwide, and believes it has demonstrated that its technology is
safe and effective in stimulating healing in chronic conditions of the foot
(plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S.
Class III PMA approved OssaTron® device, as well as stimulating bone and
chronic tendonitis regeneration in the musculoskeletal environment through the
utilization of its OssaTron, Evotron® and orthoPACE® devices in
Europe, Asia and Asia/Pacific. In addition, there are license/partnership
opportunities for SANUWAVE’s shockwave technology for non-medical uses,
including energy, water, food and industrial markets.
Forward-Looking
Statements
This press
release may contain “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, such as statements relating
to financial results and plans for future business development activities, and
are thus prospective. Forward-looking statements include all statements that
are not statements of historical fact regarding intent, belief or current
expectations of the Company, its directors or its officers. Investors are
cautioned that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, many of which are beyond the
Company’s ability to control. Actual results may differ materially from those
projected in the forward-looking statements. Among the key risks, assumptions
and factors that may affect operating results, performance and financial
condition are risks associated with the regulatory approval and marketing of
the Company’s product candidates and products, unproven pre-clinical and
clinical development activities, regulatory oversight, the Company’s ability to
manage its capital resource issues, competition, and the other factors
discussed in detail in the Company’s periodic filings with the Securities and
Exchange Commission. The Company undertakes no obligation to update any
forward-looking statement.
For additional
information about the Company, visit www.sanuwave.com.
Contact:
Millennium
Park Capital LLC
Christopher Wynne
312-724-7845
cwynne@mparkcm.com
SANUWAVE
Health, Inc.
Kevin Richardson II
CEO and Chairman of the Board
978-922-2447
investorrelations@sanuwave.com
